Ongoing Research

 
News Articles for Ongoing Research top ^
2014/12/12
Ivanhoe Energy provides update on the status of ongoing strategic and financial initiatives to obtain additional financing Canada NewsWire Company does not expect to make the cash interest payment due December 31 on convertible debentures VANCOUVER , Dec.
Sign-up for Ivanhoe Energy provides update on the status of ongoing strategic and financial initiatives to obtain additional financing investment picks
Durable Responses Observed with Patients on Study for up to Eight Months and Ongoing in Advanced Acute Myeloid Leukemia and Other Blood Cancers SAN FRANCISCO, Dec.
Sign-up for Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies investment picks
PNM Resources (NYSE: PNM) will announce the company's 2015 ongoing earnings guidance range prior to the market opening on Monday, Dec.
Sign-up for PNM Resources to Announce 2015 Ongoing Earnings Guidance Dec. 15 investment picks
2014/12/12
Company does not expect to make the cash interest payment due December 31 on convertible debentures VANCOUVER , Dec.
Sign-up for Ivanhoe Energy provides update on the status of ongoing strategic and financial initiatives to obtain additional financing investment picks
Clovis Oncology (NASDAQ:CLVS) today announced preliminary Phase 2 results from the ARIEL2 ( A ssessment of R ucaparib I n Ovarian Canc e r Tria l ) study and updated results from the ongoing Phase 1/2 monotherapy study of rucaparib.
Sign-up for Data from Ongoing Phase 2 Studies of Rucaparib in Ovarian Cancer Demonstrate Safety and Clinical Activity, Validate Differentiated Strategy investment picks
2014/10/22
Inter Parfums, Inc. (NASDAQ GS:IPAR) today announced that for the three months ended September 30, 2014, net sales of the Company’s ongoing brands (excluding Burberry brand sales) increased 6.0% to $134.2 million, as compared to $126.6 million for the corresponding period of the prior year.
Sign-up for Inter Parfums, Inc. Reports 6% Increase in Third Quarter Sales from Ongoing Brands investment picks
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers presented data from clinical trials of Soliris ® (eculizumab) in patients with atypical hemolytic uremic syndrome (aHUS), as well as an update from the Global aHUS Registry, at Kidney Week 2014, the annual meeting of the American Society of Nephrology, in Philadelphia.
Sign-up for Longer-term Outcome Data from the Largest Prospective Trial of Soliris® (eculizumab) in aHUS Underscore the Effectiveness of Ongoing Soliris Treatment investment picks
Hydrocarb Energy Corporation (OTCQB: HECC) confirmed ongoing discussions with several international energy firms expressing interest in the company’s Owambo Basin Concession in Namibia.
Sign-up for Hydrocarb Energy Corporation Announces Ongoing Joint Venture Discussions investment picks
We Love Olive Garden's Pasta, Soup, Salad and Breadsticks Too ORLANDO, Fla.
Sign-up for "Grazie" Olive Garden Guests And Fans For Your Passionate And Ongoing Support investment picks
2014/9/18
Comcast mandates new measures designed to reduce water use in California by 10 million gallons per year as part of a broader resource-conservation effort LIVERMORE, Calif.
Sign-up for Comcast Announces Ongoing Water-Saving Initiative In California investment picks
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that clinical data from a Phase 1 study of AG-120, an orally available, selective, potent inhibitor of the mutated IDH1 protein, will be highlighted in a late breaking oral presentation at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place November 18 - 21, 2014, in Barcelona, Spain.
Sign-up for Agios Pharmaceuticals to Present Clinical Data from AG-120 Ongoing Phase 1 Study in Hematologic Malignancies at EORTC-NCI-AACR 2014 investment picks
2014/9/30
ELKHART, Ind.
Sign-up for Skyline Corporation Comments On Its Ongoing Evaluation Of Strategic Initiatives investment picks
2014/10/7
To further accelerate the brand’s growth and strengthen its message touting the cultural connection TV entertainment can provide, DishLATINO has secured Mexican actor and director Eugenio Derbez to star in its new multifaceted advertising creative, part of the brand’s overall “Me Conviene” campaign.
Sign-up for DishLATINO Partners with Eugenio Derbez to Enhance Ongoing “Me Conviene” Campaign investment picks
Major infrastructure investments , including pipelines, offices and housing, are keeping major oil companies interested in Texas’ Permian Basin despite softening oil prices in recent weeks, and Taylor Consulting Inc. (OTCBB:TAYO) CEO Scott Wheeler says the company isn’t slowing down its real estate acquisition plans in the Cline Shale area in the western part of the state.
Sign-up for ‘What’s Good for the Oil Business is Good for TAYO,’ CEO Says of Ongoing Infrastructure Investments in West Texas investment picks
Company Moves Into Larger Space in New Signature Building in 22@Barcelona Technology Park that, Over Time, will Enable Employee Capacity to Grow from 450 to 700 People ROSELAND, N.J. , and BARCELONA, Spain , Nov.
Sign-up for ADP® Announces Expansion in Spain to Meet Ongoing Client Needs for Human Capital Management Technology and Expertise Around the World investment picks
Clovis Oncology (NASDAQ:CLVS) today announced initial Phase 2 results from the ARIEL2 (Assessment of Rucaparib In Ovarian Cancer Trial) study.
Sign-up for Initial Data from Ongoing Phase 2 ARIEL2 Study of Rucaparib in Ovarian Cancer Demonstrate Encouraging Clinical Activity and Safety in both BRCA Mutant and BRCAness Patients investment picks
2014/12/2
New and Updated Results Show 50% Response Rate in 14 Cardiac-Evaluable Patients New Data Show 43% Best Response Rate in 14 Renal-Evaluable Patients Cardiac and Renal Biomarker Responses of Single-Agent NEOD001-Treated Patients Compare Favorably with Historical Data in Patients with AL Amyloidosis NEOD001 Continues to be Safe and Well-Tolerated, with No Dose Limiting Toxicities Observed Excellent Pharmacokinetic Properties and No Immunogenicity Currently Enrolling Expansion Portion of Phase 1/2 Trial with New Data Expected to be Presented Annually at Appropriate Medical Conferences, Beginning in 2015 Prothena to Host Investor Conference Call and Webcast Today at 4:30 p.m. ET DUBLIN, Ireland, Dec.
Sign-up for Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis investment picks
http://media.marketwire.com/attachments/201211/99925_41732_threshold.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163477&ProfileId=051205&sourceType=1 SAN FRANCISCO, CA --
Sign-up for Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD") in Patients With Relapsed/Refractory Multiple Myeloma Presented at ASH Annual Meeting investment picks
100% of evaluable CLL/SLL patients (9/9) had nodal reductions, with 6 of 9 patients achieving a PR with the remaining 3 patients on study with nodal reductions ranging from 15% to 45% and a peripheral response (normalization or >50% decrease in ALC) pending additional assessments 83% (5/6) of patients with Non-Hodgkin's Lymphoma; 3/3 DLBCL and 2/3 Follicular Lymphoma (FL) responded to the combination at the highest dose tested, including 2 CR's in patients with DLBCL confirmed by independent review Collectively, 87 patients have been treated with TGR-1202, alone or in combination with TG-1101, without the observance of drug-related hepatic toxicity Dose escalation continues with TGR-1202 at 800mg micronized The combination of TG-1101, TGR-1202, and ibrutinib ("Triple Therapy") was safely administered to 5 patients with heavily pre-treated NHL, CLL, and Richter's transformation with no dose limiting toxicities observed, and no Grade 3 or 4 events observed to
Sign-up for Preliminary Data From Ongoing Phase I/II Dose Escalation Study of TG-1101 (Ublituximab) in Combination With TGR-1202 in Heavily Pre-treated Relapsed/Refractory B-Cell Malignancies Demonstrates Encouraging Clinical Activity and Safety investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Ongoing Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: ONEOK Partners  |  Next: Online Banking